Anti-Covid-19 Phytochemicals
DOI:
https://doi.org/10.22270/ajprd.v8i6.807Keywords:
Phytochemical, Covid-19, IC50, Binding affinity, Structural resemblance.Abstract
The Phytochemicals are the future phytomedicine for Covid-19 virus, therefore their antiviral affinity was differently viewed.
Downloads
References
2. Bosch, B. j., van der zee, r, de haan, C. A. and Rottier, P. J. (2003). The coronavirus spike protein is a class I virus fusion protein: Structural and functional characterization of the fusion core complex. Journal of Virology. 77(16), 8801-8811. https://doi.org/10.1128/jvi.77.16.8801-8811.2003
3. Zhang. L, Shen. F. M. Chen, F. and Lin, Z (2020). Origin and evolution of the 2019 novel coronavirus Clinical infectious Diseases, ciaa112. https://doi.org/10.1093/cid/ciaa112
4. Schoeman, D., and Fielding, B. C. (2019). Coronavirus envelop protein: Current knowledge. Virology Journal, 16, 69. https://doi.org/10.1186/s12985-019-1182-0
5. SARS-CoV replication. Journal of Traditional and Complementary Medicine, 1(1), 41-50. https://doi.org/10.1016/s225-4110(16)30055-4
6. Ganjhu, R. K., Mudgal, P. P., Maity, H., Dowarha, D., Devadiga, S., Nag., S., and Arunkumar, G. (2015). Herbal plants and plant preparations as remedial approach for viral diseases. Virus, 26(4), 225-236. https:// doi.org/10.1007/s13337-015-0276-6
7. Denaro, M., Smeriglio, A, Barreca, D., De Francesco, C., Occhiuto, C., Milano, G., and Trombetta, D. (2019). Antiviral activity of plants and their isolated bioactive compounds: An update. PhytotherapyResearch.https://doi.org/10.1002/ptr.6575
8. Wen C. C., Kuo, Y. H., Jan, J. T., Liang, P. H., Wang, S. Y., Liu, H. G.,.. Yang, N. S. (2007). Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. Journal of medicinal Chemistry, 50, 4087-4095. https://doi.org/10.1021/jm070295s
9. Cao, J, Forrest, J.C, and Zhang. X. (2015). A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Research, 114, 1-10. https://doi.org/10.1016/j.Antiviral.2014.11.010
10. Kannan, S., Shaik Syed Ali, P., Sheeza, A., and Hemalatha, K. (2020). COVID-19 (novel coronavirus 2019)- Recent trends. European Review for Medical and Pharmacological Science, 24, 2006-2011. https://doi.org/10.26355/eurrev-202002-20378
11. Li, S, Y, Chen, C., Zhang. H. Q, Guo, H. y., Wang. L…. Tan, X.(2005). Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Research, 67, 18-23. https://doi.org/10.1016/j.antiviral.2005.02.007
12. 23386 | RSC Adv., 2020, 10, 23379-23393
13. Luv Kush et.al AJPRD 8(4) 88-90 , 2020.
14. Muhammad Tahir ulQamar, Safar M. Alqahtani, Mubarak A. Alamri, Ling-Ling Chen. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants.February 2020 Journal of Pharmaceutical Analysis 10(4).https://doi.org/10.1016/j.jpha.2020.03.009
15. K.-C. Chou, D.-Q. Wei, and W.-Z. Zhong, ̎Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS,” Biochemical and biophysical research communications, vol. 308, no.l, pp. 148-151,2003.
16. De Haan, C. A, and Rottier, P. J (2005). Molecular interactions in the assembly of coronaviruses. Advances in virus Research, 64, 165-230. https://doi.org/10.1016/S0065-3527(05)64006-7
17. Bacha, U.; Barrila, J.; Velazquez-Campoy, A.; Leavitt, S. A.; Freire, E., Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry-Us 2004, 43, 4906-4912.
18. Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J. R.; Hilgenfeld, R., Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003, 300, 1763-1767.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.